Fall COVID-19 Boosters Are around the Corner – What Our System Says about the Companies Making Them

[TradeSmith Daily]( Fall COVID-19 Boosters Are around the Corner – What Our System Says about the Companies Making Them With the summer season coming to a close, health officials are looking ahead and worrying that the colder months will bring a resurgence of COVID-19 cases. As you can see in the chart below, in January 2021 and January 2022, the United States experienced two large peaks in hospitalized COVID-19 patients. In an effort to minimize hospitalizations, the Food and Drug Administration has authorized Pfizer Inc. (PFE) and Moderna Inc. (MRNA) to roll out millions of new COVID-19 boosters. These boosters will target not only the original strain but also the omicron subvariants, BA.4 and BA.5. Pfizer generated $36.7 billion in sales last year from its COVID-19 vaccine, and Moderna’s vaccine generated $17.7 billion in sales. For 2022, Pfizer is expecting less revenue from vaccine sales but still a massive $32 billion, while Moderna is projecting an increase in sales to $19 billion. With this fresh news that the booster shots were just approved, I wanted to put Pfizer and Moderna through our system, as it has offered powerful guidance on what to do and when to do it for years now. RECOMMENDED LINK [“Inflation Assassin” Releases His Biggest Prediction Yet]( Some know Mike Burnick as the “Inflation Assassin”... If you haven’t seen his appearances on Fox Business, Barron’s, or on CNBC... Then you’ll likely be hearing about his controversial new interview in [this episode of ‘Armchair Millionaire’ (video)](. Mike just took the internet by storm with his new prediction: “An imminent ‘Flatline Shock’ is coming. Fail to prepare, and you could have 86% LESS money in your account.” [Click here to watch his free presentation right now]( Pfizer and Moderna Put to the Test With Pfizer, our system triggered its most recent Entry Signal (green “E”) on May 13, 2021, when the stock was trading for $38.48. It then entered the Red Zone (red bell) on Feb. 22, 2022, at $46.92. For anyone following along, that would have been a 21.93% profit in less than 10 months. And anyone using our system to trade Moderna made even more money. Between its Entry Signal in December 2019 and entering the Red Zone in January 2022, the stock returned a stellar 879% windfall. But currently, both of these stocks are in the Red Zone, and MRNA has a sky-high-risk Volatility Quotient (VQ) of 65.67%. As we can see from the previous examples, those who trusted our system were rewarded mightily. And I’m trusting it now when it says to stay away from both PFE and MRNA. Of course, just as important as knowing what to stay away from is knowing what opportunities to add to your radar. When I ran a search through our Screener tool, one health care stock popped up in our Green Zone. Focus on Broad Health Care Instead of focusing on companies that just create pills and vaccines, considering WHERE people go to receive medicine, wellness products, and health services can reveal a broader opportunity. That led me to CVS Health Corp. (CVS) and its massive reach in the health care world. The company got its start in 1963 by selling health and beauty products, but anyone still viewing this as a generic drugstore chain has missed CVS’s transformation into a health care juggernaut. CVS 2021 Annual Report It’s becoming a one-stop shop where doctors, insurance companies, and pharmacies can more easily share information, giving people a reason to exclusively use CVS. CVS acquired the health insurance company Aetna in 2018, which incentivizes those with Aetna to use CVS because medical information is easily shared between the insurance company and CVS Pharmacy. It also acquired the specialty pharmacy company Apothecary By Design in 2018. In terms of medical evaluations and treatment, CVS offers an array of in-person services at certain locations. CVS.com Its COVID-19 vaccines and testing alone led to 43 million new CVS customers, and 15% of customers new to CVS through testing services chose to fill new prescriptions or receive vaccinations through CVS. RECOMMENDED LINK [Bitcoin won't make you rich]( Some people believe Bitcoin will make you rich... But they’re wrong. That wave has already been missed. And now the man who picked Bitcoin at $369 all the way back in 2014... Has his sights set on a [small $2 coin set to soar in the next crypto bull run]( which could start as soon as the end of the month. This coin is at the forefront of a $30 trillion shock wave set to hit the market, and the world’s smartest billionaire investors like Jeff Bezos, Mark Zuckerberg, Mark Cuban, and Bill Gates are all moving their money as we speak. There is no time to waste. [Click here to learn all the details]( Final Thoughts CVS has quietly been building itself a moat, as not many other companies have the competitive advantage of offering on-site care, a connected insurance system, and a pharmacy all in one place. It’s also in the running to acquire another company that would give it an additional advantage in the “home-based health” services market, [which you can find out more about here](. While it is on the smaller side, CVS’s dividend of 2.18% rewards investors with income in the here and now. The stock is currently in our Green Zone, and CVS is also in the portfolio of three billionaires that we track. Have a great Thursday, [Keith Kaplan]Keith Kaplan CEO, TradeSmith P.S. Give your investment portfolio a much-needed a shot in the arm by taking advantage of a rare financial event that could happen as soon as the end of this month. It’s got one multimillionaire crypto analyst banging the table about a tiny $2 coin. [Click here]( to learn how to prepare for what might be the last profit opportunity of this magnitude that you’ll see in a long while. Best of TradeSmith The chart below represents the best-performing open positions over the last two years, as recommended by our software. [Download now on the Apple Store]( [Get It On Google Play]( [866.385.2076](tel:+866-385-2076) | support@tradesmith.com ©TradeSmith, LLC. All Rights Reserved. You may not reproduce, modify, copy, sell, publish, distribute, display or otherwise use any portion of the content without the prior written consent of TradeSmith. TradeSmith is not registered as an investment adviser and operates under the publishers’ exemption of the Investment Advisers Act of 1940. The investments and strategies discussed in TradeSmith’s content do not constitute personalized investment advice. Any trading or investment decisions you take are in reliance on your own analysis and judgment and not in reliance on TradeSmith. There are risks inherent in investing and past investment performance is not indicative of future results. TradeSmith P.O. Box 3039 Spring Hill, FL 34611 [Terms of Use]( [Privacy Policy]( To unsubscribe or change your email preferences, please [click here](. [tradesmith logo]